Our corporate concept is that I will be the Leading Light for Life to deliver world type state of the art pharmaceuticals that offer people from round the world a healthier life. Through our experience in these drug discovery programs and subsequent clinical trials, we’d fostered the notion that we should provide novel solutions for increasing the health of well defined populations of patients experiencing several cancers. We call it the precision medicine approach. Perfection medicine is becoming a treatment option for certain cancers. In July 2011, Drug Administration and the US Food released the draft guidance for in vitro friend analytical devices. In August 2011, the FDA permitted ZelborafTM, a kinase inhibitor, for treating patients with unresectable or metastatic melanoma whose tumors express a gene mutation called BRAF V600E together with a diagnostic test to identify such mutation in patients Gene expression melanoma cells. The FDA also accepted Xalkoriw, a kinase inhibitor, for treating patients with locally high level or metastatic non small cell lung cancer who express the abnormal anaplastic lymphoma kinase gene together with a diagnostic test to detect such abnormal gene Astellas has three sites for oncology drug discovery, particularly Astellas Pharma Inc. Tsukuba Research Center at Tsukuba, Ibaraki, Japan, OSI Pharmaceuticals, LLC at Farmingdale, Nyc, Us, and Agensys, Inc. at Santa Monica, CA, USA. The three research websites follow precision medicine in a diverse manner based on the research system and research strategy of every site. Tsukuba Research Center Lenalidomide solubility targets the development of small molecules that inhibit the function of molecules which are necessary for the survival or development of tumor cells as a result of either genetic or epigenetic alterations to the drug goal molecules themselves or in the presence of certain genetic or epigenetic contexts. In order to produce drugs to well defined patient populations, Tsukuba Research Center is placing major emphasis on efforts to identify and verify novel molecular targets based on internally research and external partnerships. It ought to be noted these target discovery efforts also form the cornerstone of translational analysis for determination of the right patients. Predicated on this research style, we made ASP3026, an inhibitor of ALK tyrosine kinase. OSI joined Astellas this season, and it is pursuing little molecule drug discovery with a different type using different precision medicine techniques. During the growth of erlotinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, OSI finished much research to better understand which patients well benefit from this therapy and which patients would become refractory or resistant.